VERTEX PHARMACEUTICALS INC / MA 8-K

What Happened

• On July 6, 2026, Vertex Pharmaceuticals Incorporated (Parent) and its wholly owned merger subsidiary entered into an Agreement and Plan of Merger to acquire Crinetics Pharmaceuticals, Inc. Under the deal, each outstanding Crinetics share will be converted into the right to receive $85.00 per share in cash (subject to withholding and limited exceptions). The parties expect the transaction to close in Q3 2026.

Key Details

• Purchase price: $85.00 cash per share for outstanding Crinetics common stock (excluding company-held shares, Parent/Merger Sub shares, and shares validly exercising appraisal rights).
• Employee equity treatment: all outstanding unvested stock options and restricted stock units vest immediately prior to the closing; vested awards will be cashed out at closing (options in-the-money receive the spread; options with exercise price ≥ $85 are canceled for no consideration).
• Financing: Vertex entered a debt commitment letter for a $4.5 billion unsecured 364‑day bridge loan from Bank of America, BofA Securities and Morgan Stanley Senior Funding to help finance the deal; Vertex expects to use cash on hand and new debt financing, and the merger is not conditioned on obtaining the bridge financing.
• Closing conditions & timing: closing is subject to customary conditions, including Crinetics stockholder approval (majority vote), expiration of HSR and any required foreign clearances, no continuing material adverse effect, and satisfaction of other customary representations, covenants and closing conditions. The agreement contains a long‑stop date of January 6, 2027 (with possible extension in certain cases).
• Termination fee: under specified circumstances the Company may owe Vertex a termination fee of $350,474,425.

Why It Matters

• For Crinetics shareholders: the agreement provides a definitive cash exit at $85 per share, vesting and cashing out unvested equity, subject to shareholder approval and standard closing conditions. Shareholders who prefer appraisal rights are carved out where applicable.
• For Vertex investors: the acquisition is intended to add Crinetics’ assets to Vertex’s portfolio (press materials cite product and revenue potential), and Vertex has arranged a committed bridge facility to support closing. However, completion still depends on regulatory clearance, shareholder vote and other conditions; the agreement includes a sizable termination fee and customary protections.